ESBL-producing E. coli and K. pneumoniae: prevalence and antimicrobial susceptibility

• Published in: Microbiologia Medica Vol. 24; no. 3
• Main Authors: Giuseppe Miragliotta, Anna Di Taranto, Rossella De Nittis, Raffaele Antonetti, Raffaele Del Prete, Adriana Mosca
• Format: Journal Article
• Language: English
• Published: PAGEPress Publications 30.09.2009
• Subjects: E. coli, K. pneumoniae, ESBL, sensibilità antibiotica
• ISSN: 2280-6423
• DOI: 10.4081/mm.2009.2530

Infections caused by extended-spectrum beta-lactamase (ESBL) producing E. coli and K. pneumoniae limit therapeutical options.The objective of this study was to evaluate the activity of ciprofloxacin, imipenem, amikacin and piperacillin/tazobactam against ESBL-producing E. coli and K. pneumoniae strains isolated from patients admitted to Ospedali Riuniti, Foggia, over the period January-December 2007. A total of 1013 E. coli and 146 K. pneumoniae were isolated from various clinical specimens. 111/1013 (10.9%) and 24/146 (16.4%) were confirmed as ESBL-producing strains by both the Phoenix system (Becton & Dickinson) and the E-test (bioMérieux, Italia). Both the ESBL producing enterobacteria showed a high degree resistance to ciprofloxacin; in addition, K. pneumoniae exhibited resistance also to piperacillin/tazobactam. Imipenem was the most effective antibiotic with the exception of one strain ESBL-positive K. pneumoniae. A similar pattern was showed by amikacin. In view of the increasing prevalence of ESBL strains it appears important a continuous antimicrobial monitoring.